Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?

ISSN: 1873-4286 (Online)
ISSN: 1381-6128 (Print)

Volume 23, 46 Issues, 2017

Download PDF Flyer

Current Pharmaceutical Design

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 73rd of 253 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

William A. Banks
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.052
5 - Year: 3.132

Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?

Current Pharmaceutical Design, 20(10): 1422-1449.

Author(s): Lucy Sanchez-Covarrubias, Lauren M. Slosky, Brandon J. Thompson, Thomas P. Davis and Patrick T Ronaldson.

Affiliation: Department of Medical Pharmacology, College of Medicine, University of Arizona, 1501 North Campbell Avenue, P.O. Box 245050, Tucson, AZ, 85724-5050.


The blood-brain barrier (BBB) and blood-cerebrospinal fluid (BCSF) barriers are critical determinants of CNS homeostasis. Additionally, the BBB and BCSF barriers are formidable obstacles to effective CNS drug delivery. These brain barrier sites express putative influx and efflux transporters that precisely control permeation of circulating solutes including drugs. The study of transporters has enabled a shift away from “brute force” approaches to delivering drugs by physically circumventing brain barriers towards chemical approaches that can target specific compounds of the BBB and/or BCSF barrier. However, our understanding of transporters at the BBB and BCSF barriers has primarily focused on understanding efflux transporters that efficiently prevent drugs from attaining therapeutic concentrations in the CNS. Recently, through the characterization of multiple endogenously expressed uptake transporters, this paradigm has shifted to the study of brain transporter targets that can facilitate drug delivery (i.e., influx transporters). Additionally, signaling pathways and trafficking mechanisms have been identified for several endogenous BBB/BCSF transporters, thereby offering even more opportunities to understand how transporters can be exploited for optimization of CNS drug delivery. This review presents an overview of the BBB and BCSF barrier as well as the many families of transporters functionally expressed at these barrier sites. Furthermore, we present an overview of various strategies that have been designed and utilized to deliver therapeutic agents to the brain with a particular emphasis on those approaches that directly target endogenous BBB/BCSF barrier transporters.


ATP-binding cassette transporters, blood-brain barrier, blood-cerebrospinal fluid barrier, drug delivery, neurovascular unit, solute carriers, transporters.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 20
Issue Number: 10
First Page: 1422
Last Page: 1449
Page Count: 28
DOI: 10.2174/13816128113199990463
Price: $58
4th Microbiome R&D and Business Collaboration Forum: EuropeRNA Therapeutics 2017

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science